Home > Inhibitors & Agonists > Metabolic Enzyme/Protease > Isocitrate Dehydrogenase (IDH)
Cat. No. Product name CAS No.
DC8051 AG-120 (Ivosidenib)

AG-120 is a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein.

DC8374 AG-221(Enasidenib)

AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein.

DC10439 Vorasidenib (AG881)

AG-881 is a potent and selective orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1) in the cytoplasm and type 2 (IDH2).

DC5050 AGI-5198

AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.

DC7174 AGI-6780

AGI-6780 is the first highly potent and selective small molecule inhibitor of isocitrate dehydrogenases, which binds in an allosteric manner at the dimer interface of mutant IDH2-R140Q (IC50=23 nM).

DC11719 BAY-1436032

BAY-1436032 (BAY1436032) is a potent, selective, orally available inhibitor of pan-mutant IDH1 with IC50 of 15 nM for both IDH1 R132H and R132C, respectively.

DC10538 IDH-305

IDH305 is an inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity.

DC10830 IDH-889

IDH889 is a potent and selective inhibitors of IDH1. IDH899 shows IDH (R132H) IC50 = 20 nM; Cell 2-HG IC50 = 14 nM.

DC7982 Mutant IDH1-IN-1

Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent).

DC12281 Olutasidenib (FT-2102)

Olutasidenib is a highly potent, selective inhibitor of mutant Isocitrate dehydrogenase (IDH)1 that could be used in the treatment of acute myeloid leukemia.

Page 1 / Total 1 FirstPrevNextLastGoto